BRAF V600 Mutation Analysis, Tissue

Overview

BRAF V600 Mutation Analysis is a molecular diagnostic test performed on tissue samples to detect mutations in the BRAF gene, particularly the V600E and related V600 variants. These mutations are associated with several cancers and help guide targeted therapy decisions.

This test plays a critical role in personalized cancer treatment by identifying patients who may benefit from BRAF inhibitor therapies.

Why This Test is Done

• Detects BRAF V600 mutations in tumor tissue
• Helps in selecting targeted cancer therapies
• Assists in diagnosis and prognosis evaluation
• Supports treatment planning and monitoring
• Useful in identifying eligibility for precision medicine

Common Conditions Associated

• Melanoma
• Colorectal cancer
• Thyroid carcinoma
• Non-small cell lung cancer (NSCLC)
• Hairy cell leukemia
• Other solid tumors

Sample Required

• Specimen: Tumor Tissue
• Method: Molecular Analysis / PCR / Sequencing based techniques
• Preparation: Usually no special preparation required

Key Benefits

• Accurate detection of actionable mutations
• Enables personalized targeted treatment
• Improves therapy selection
• Assists oncologists in precision medicine decisions
• Supports better clinical management

Interpretation

• Positive: BRAF V600 mutation detected
• Negative: No detectable BRAF V600 mutation identified
• Results should always be interpreted along with clinical findings, pathology, and oncologist evaluation.

Turnaround Time

Typically 5–10 working days depending on laboratory workflow.

Recommended For

• Patients diagnosed with specific cancers requiring molecular profiling
• Individuals being evaluated for targeted therapy
• Oncology treatment planning and prognosis assessment

Safety Information

• Laboratory test only
• Requires properly preserved tissue specimen
• Should be interpreted by qualified healthcare professionals

Tags

#BRAF #BRAFV600 #MutationAnalysis #CancerGenetics #Oncology #TargetedTherapy #MolecularDiagnostics #PrecisionMedicine